

**Amended Claims**

**Claims 1-5 (canceled).**

6. **(previously presented)** A method for administering a live attenuated bacterial vaccine to a mammal, wherein the method comprises injecting into a submucosal layer of the mammal an immunogenically effective amount of the vaccine.

7. **(previously presented)** The method according to claim 6, wherein the live attenuated bacterium of the vaccine is selected from the group consisting of *Actinobacillus equuli*, *Actinobacillus pleuropneumoniae*, *Actinomyces pyogenes*, *Bordetella bronchiseptica*, *Brucella abortus*, *Clostridium perfringens*, *Corynebacterium bovis*, *Corynebacterium pseudotuberculosis*, *Erysipelothrix rhusiopathiae*, *Escherichia coli*, *Haemophilus parasuis*, *Leptospira canicola*, *Leptospira hardjo*, *Leptospira icterohaemorrhagiae*, *Leptospira pomona*, *Mycobacterium bovis*, *Mycoplasma bovis*, *Mycoplasma hyopneumoniae*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pseudomonas mallei*, *Rhodococcus equi*, *Salmonella choleraesuis*, *Salmonella dublin*, *Salmonella typhimurium*, *Serpulina hyodysenteriae*, *Staphylococcus aureus*, *Streptococcus agalactiae*, *Streptococcus equi*, *Streptococcus pneumoniae*, *Streptococcus suis*, *Streptococcus uberis*, and *Streptococcus zooepidemicus*.

8. **(previously presented)** The method according to claim 6, wherein the mammal is a horse.

9. **(previously presented)** A method for reducing the amount of adverse reactions in a mammal at an injection site of a live attenuated bacterial vaccine, wherein:

the method comprises administering submucosally the vaccine, whereby the amount of adverse reactions at the injection site is reduced,

the live bacterial vaccine comprises bacteria that cause abscess formation when administered intramuscularly, and

the reduction of the amount of adverse reactions is measured by the amount or size of abscesses or lesions at the mucosal injection site compared to an intramuscular injection site.

10. **(previously presented)** The method according to claim 9, wherein the vaccine is administered into the submucosa of the labiae.

11. **(previously presented)** The method according to claim 9, wherein the live attenuated bacterium of the vaccine is selected from the group consisting of *Actinobacillus equuli*, *Actinobacillus pleuropneumoniae*, *Actinomyces pyogenes*, *Bordetella bronchiseptica*, *Brucella abortus*, *Clostridium perfringens*, *Corynebacterium bovis*, *Corynebacterium pseudotuberculosis*, *Erysipelothrix rhusiopathiae*, *Escherichia coli*, *Haemophilus parasuis*, *Leptospira canicola*, *Leptospira hardjo*, *Leptospira icterohaemorrhagiae*, *Leptospira pomona*, *Mycobacterium bovis*, *Mycoplasma bovis*, *Mycoplasma hyopneumoniae*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pseudomonas mallei*, *Rhodococcus equi*, *Salmonella cholerasuis*, *Salmonella dublin*, *Salmonella typhimurium*, *Serpulina hyodysenteriae*, *Staphylococcus aureus*, *Streptococcus agalactiae*, *Streptococcus equi*, *Streptococcus pneumoniae*, *Streptococcus suis*, *Streptococcus uberis*, and *Streptococcus zooepidemicus*.

12. **(previously presented)** The method according to claim 6, wherein the live attenuated bacterium of the vaccine is selected from the group consisting of *Actinobacillus pleuropneumoniae*, *Bordetella bronchiseptica*, *Brucella abortus*, *Clostridium perfringens*, *Corynebacterium pseudotuberculosis*, *Erysipelothrix rhusiopathiae*, *Escherichia coli*, *Mycobacterium bovis*, *Mycoplasma hyopneumoniae*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Rhodococcus equi*, *Salmonella cholerasuis*, *Salmonella dublin*, *Salmonella typhimurium*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus suis*, and *Streptococcus uberis*.

13. **(previously presented)** The method according to claim 12, wherein the mammal is a horse.

14. **(previously presented)** The method according to claim 12, wherein the mammal is a ruminant.

15. **(previously presented)** The method according to claim 12, wherein the mammal is a pig.

16. **(previously presented)** The method according to claim 12, wherein the mammal is a dog.

17. **(previously presented)** The method according to claim 6, wherein the mammal is a ruminant.

18. **(previously presented)** The method according to claim 6, wherein the mammal is a pig.

19. **(previously presented)** The method according to claim 6, wherein the mammal is a dog.

20. **(previously presented)** The method according to claim 9, wherein the live attenuated bacterium of the vaccine is selected from the group consisting of *Actinobacillus pleuropneumoniae*, *Bordetella bronchiseptica*, *Brucella abortus*, *Clostridium perfringens*, *Corynebacterium pseudotuberculosis*, *Erysipelothrix rhusiopathiae*, *Escherichia coli*, *Mycobacterium bovis*, *Mycoplasma hyopneumoniae*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Rhodococcus equi*, *Salmonella choleraesuis*, *Salmonella dublin*, *Salmonella typhimurium*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus suis*, and *Streptococcus uberis*.

21. **(currently amended)** A method for systemic application of live attenuated bacteria to a mammal, wherein:

the method comprises administering the live attenuated bacteria submucosally to the mammal,

the live attenuated bacteria cause abscess and/or lesion formation in the mammal if the live attenuated bacteria are instead administered intramuscularly or intradermally to the mammal, and

any abscess and/or lesion formation at the site of the submucosal administration is less in total size than the abscess and/or lesion formation that would occur if the bacteria are instead administered intramuscularly or **intradermally intradermally** to the mammal.

**22. (previously presented)** A method according to claim 21, wherein the live attenuated bacteria cause abscess and/or lesion formation in the mammal if the live attenuated bacteria are administered intramuscularly to the mammal.

**23. (previously presented)** The method according to claim 21, wherein the live attenuated bacteria are selected from the group consisting of *Actinobacillus equuli*, *Actinobacillus pleuropneumoniae*, *Actinomyces pyogenes*, *Bordetella bronchiseptica*, *Brucella abortus*, *Clostridium perfringens*, *Corynebacterium bovis*, *Corynebacterium pseudotuberculosis*, *Erysipelothrix rhusiopathiae*, *Escherichia coli*, *Haemophilus parasuis*, *Leptospira canicola*, *Leptospira hardjo*, *Leptospira icterohaemorrhagiae*, *Leptospira pomona*, *Mycobacterium bovis*, *Mycoplasma bovis*, *Mycoplasma hyopneumoniae*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pseudomonas mallei*, *Rhodococcus equi*, *Salmonella choleraesuis*, *Salmonella dublin*, *Salmonella typhimurium*, *Serpulina hyodysenteriae*, *Staphylococcus aureus*, *Streptococcus agalactiae*, *Streptococcus equi*, *Streptococcus pneumoniae*, *Streptococcus suis*, *Streptococcus uberis*, and *Streptococcus zooepidemicus*.

**24. (previously presented)** The method according to claim 21, wherein the live attenuated bacteria are selected from the group consisting of *Actinobacillus pleuropneumoniae*, *Bordetella bronchiseptica*, *Brucella abortus*, *Clostridium perfringens*, *Corynebacterium pseudotuberculosis*, *Erysipelothrix rhusiopathiae*, *Escherichia coli*, *Mycobacterium bovis*, *Mycoplasma hyopneumoniae*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Rhodococcus*

*equi*, *Salmonella choleraesuis*, *Salmonella dublin*, *Salmonella typhimurium*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus suis*, and *Streptococcus uberis*.

25. **(previously presented)** The method according to claim 21, wherein the mammal is a horse.

26. **(previously presented)** The method according to claim 21, wherein the mammal is a ruminant.

27. **(previously presented)** The method according to claim 21, wherein the mammal is a pig.

28. **(currently amended)** The method according to claim **[[1]] 21**, wherein the mammal is a dog.